Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
The postantifungal effect (PAFE) of fluconazole, MK-0991, LY303366, and amphotericin B was determined against isolates of Candida albicans and Cryptococcus neoformans. Concentrations ranging from 0. 125 to 4 times the MIC were tested following exposure to the antifungal for 0.25 to 1 h. Combinations of azole and echinocandin antifungals (MK-0991 and LY303366) were tested against C. neoformans. Fluconazole displayed no measurable PAFE against Candida albicans or Cryptococcus neoformans, either alone or in combination with either echinocandin antifungal. MK-0991, LY303366, and amphotericin B displayed a prolonged PAFE of greater than 12 h against Candida spp. when tested at concentrations above the MIC for the organism and 0 to 2 h when tested at concentrations below the MIC for the organism.
Ernst
E J
EJ
College of Pharmacy, The University of Iowa, Department of Pathology, The University of Iowa College of Medicine, Iowa City, Iowa 52242, USA. erika-ernst@uiowa.edu
Klepser
M E
ME
Pfaller
M A
MA
D000666:Amphotericin B / Q000494:pharmacology; D000077612:Anidulafungin; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects* / Q000235:genetics; D000077336:Caspofungin; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000235:genetics; D054714:Echinocandins; D015725:Fluconazole / Q000494:pharmacology; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D010455:Peptides; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011090:Polyenes / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D011090:Polyenes; D000666:Amphotericin B; D015725:Fluconazole; D000077612:Anidulafungin; D000077336:Caspofungin